financetom
Business
financetom
/
Business
/
Toyota warns of 20% profit fall due to rising raw material costs
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Toyota warns of 20% profit fall due to rising raw material costs
May 11, 2022 5:13 AM

Toyota Motor warned "unprecedented" hikes in raw material costs could slice a fifth off full-year profit, a clear sign the world's top automaker by sales can no longer shrug off the supply-chain crunch that has roiled the global industry.

Share Market Live

NSE

Also reporting a 33 percent drop in fourth-quarter operating profit, the Japanese giant saw its shares slid more than 5 percent on Wednesday, before closing down more than 4 percent- their biggest one-day fall in two months. The Tokyo benchmark was up 0.3 percent.

Toyota had fared well during the earlier months of a global semiconductor shortage, thanks to its larger stockpile of chips, but it has now joined rivals in slashing production thanks to the prolonged crunch, as well as China's fresh COVID-19 restrictions.

The home of the famed Corolla compact car said it expects materials costs to more than double to 1.45 trillion yen ($11.1 billion) in the fiscal year that started in April, which it expected to deal with by switching to lower-cost materials.

"We need to think about how we can respond to material inflation by eliminating the distinction between original equipment manufacturers and suppliers and working together as one," chief financial officer Kenta Kon told reporters, referring to car makers.

"Since the price of materials is rising, we need to work to reduce the amount of materials we use as much as possible and to replace them with less expensive materials."

The automaker expects to sell 8.85 million vehicles globally this fiscal year, up 7.5 percent from last year. For the current fiscal year, Toyota forecast operating profit will fall about 20 percent to 2.4 trillion yen from almost 3 trillion yen in the previous year. Analysts had expected earnings to rise 12 percent to 3.36 trillion yen, according to Refinitiv.

In the January-March quarter, its profit slumped to 463.8 billion yen, also significantly below an average estimate of 521.1 billion yen. The yen's sharp depreciation to two-decade lows has worked in favour of Japan's export-driven auto industry. But the surging raw material costs and global supply chain disruptions exacerbated by China's tough COVID measures are putting pressure on profitability.

Toyota's domestic rivals Nissan Motor Co and Honda Motor Co report earnings on Thursday and Friday respectively. Nissan shares closed 1.5 percent lower on Wednesday, while Honda dropped 3.1 percent.

On Tuesday Toyota cut its global production target for May by around 50,000 vehicles to about 700,000 as it plans to suspend operations on 14 lines at eight domestic factories for up to six days this month due to the COVID lockdown in China.

The plan follows several cuts in its production plan between April and June, which had frustrated its suppliers.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
IDEXX Laboratories Authorizes Additional 5 Million Shares Buyback
IDEXX Laboratories Authorizes Additional 5 Million Shares Buyback
Dec 9, 2024
08:05 AM EST, 12/09/2024 (MT Newswires) -- IDEXX Laboratories ( IDXX ) said Monday it has approved an increase of up to five million shares under its ongoing stock buyback plan. The expansion is in addition to the 1.3 million shares remaining under IDEXX Laboratories' ( IDXX ) stock buyback plan as of Dec. 3, the company said, adding that...
AbbVie's Parkinson's disease drug meets main goal in late-stage study
AbbVie's Parkinson's disease drug meets main goal in late-stage study
Dec 9, 2024
Dec 9 (Reuters) - AbbVie ( ABBV ) said on Monday its experimental drug to treat Parkinson's Disease met the main goal in a late-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Anil D'Silva) ...
Astrazeneca Reports Positive Phase 3 Calquence Data for Chronic Lymphocytic Leukemia
Astrazeneca Reports Positive Phase 3 Calquence Data for Chronic Lymphocytic Leukemia
Dec 9, 2024
08:09 AM EST, 12/09/2024 (MT Newswires) -- Astrazeneca ( AZN ) said Sunday that results of a phase 3 trial of Calquence in combination with venetoclax demonstrated statistically significant improvement in progression-free survival in previously untreated adult patients with chronic lymphocytic leukemia, compared with standard-of-care chemoimmunotherapy. Trial results showed that the combination therapy reduced the risk of disease progression or...
Russia extends realisation period for unclaimed Exxon stake in Sakhalin-1 project until 2026, decree shows
Russia extends realisation period for unclaimed Exxon stake in Sakhalin-1 project until 2026, decree shows
Dec 9, 2024
MOSCOW, Dec 9 (Reuters) - Russian President Vladimir Putin has signed a decree extending the realisation period for the unclaimed Exxon stake in Russia's Sakhalin-1 oil and gas project until 2026. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved